Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
AETHLON MEDICAL INC amended Amendment to Pre-Funded Common Stock Purchase Warrant with institutional investor valued at Amendment removed requirement that Company obtain shareholder approval for exercise of pre-funded wa (effective 2026-01-22).
- Action
- amendment
- Agreement
- equity purchase
- Counterparty
- institutional investor
- Value
- Amendment removed requirement that Company obtain shareholder approval for exercise of pre-funded wa
- Effective
- 2026-01-22
Exact text from the filing
Also on January 22, 2026, the Company and the Purchaser entered into the Amendment to Pre-Funded Common Stock Purchase Warrant (the “PFW Amendment”). The PFW Amendment amends the terms of that certain Pre-Funded Common Stock Purchase Warrant by and between the Company and the Purchaser dated December 8, 2025 (the “Warrant”), as previously disclosed on the Current Report on Form 8-K filed by the Company on December 8, 2025. The PFW Amendment removed the requirement that Company obtain shareholder approval of issuance or exercise the pre-funded warrants under Nasdaq 5635 prior to those pre-funded warrants becoming exercisable. As a result, the pre-funded warrants are immediately exercisable.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
AETHLON MEDICAL INC amended Amendment to Securities Purchase Agreement with institutional investor valued at Amendment removed requirement that Company obtain shareholder approval for exercise of pre-funded wa (effective 2026-01-22).
- Action
- amendment
- Agreement
- equity purchase
- Counterparty
- institutional investor
- Value
- Amendment removed requirement that Company obtain shareholder approval for exercise of pre-funded wa
- Effective
- 2026-01-22
Exact text from the filing
On January 22, 2026, Aethlon Medical, Inc. (the “Company”) and an institutional investor (the “Purchaser”) entered into the Amendment to Securities Purchase Agreement (the “SPA Amendment”). The SPA Amendment amends the terms of that certain Securities Purchase Agreement by and between the Company and the Purchaser dated December 5, 2025 (the “Securities Purchase Agreement”), as previously disclosed on the Current Report on Form 8-K filed by the Company on December 8, 2025. The SPA Amendment removed the requirement that Company obtain shareholder approval of issuance or exercise the pre-funded warrants under Nasdaq 5635 prior to those pre-funded warrants becoming exercisable. As a result, the pre-funded warrants are immediately exercisable. All other terms of the Securities Purchase Agreement remain unchanged.
View on SEC.gov